AI Article Synopsis
- Solid tumors pose significant challenges for treatments like antibody-drug conjugates and immunotherapy, requiring clear and distinct targets that are more prevalent in tumors than in healthy tissues.
- Oncofetal chondroitin sulfate is a specific type of glycosaminoglycan that is primarily found in solid tumors and metastasis, originally believed to be limited to the placenta for supporting pregnancy.
- The text explores the potential of oncofetal chondroitin sulfate as a therapeutic target for childhood solid tumors, building on recent research findings from adult cancer studies over the last five years.
Article Abstract
Solid tumors remain a major challenge for targeted therapeutic intervention strategies such as antibody-drug conjugates and immunotherapy. At a minimum, clear and actionable solid tumor targets have to comply with the key biological requirement of being differentially over-expressed in solid tumors and metastasis, in contrast to healthy organs. Oncofetal chondroitin sulfate is a cancer-specific secondary glycosaminoglycan modification to proteoglycans expressed in a variety of solid tumors and metastasis. Normally, this modification is found to be exclusively expressed in the placenta, where it is thought to facilitate normal placental implantation during pregnancy. Informed by this biology, oncofetal chondroitin sulfate is currently under investigation as a broad and specific target in solid tumors. Here, we discuss oncofetal chondroitin sulfate as a potential therapeutic target in childhood solid tumors in the context of current knowhow obtained over the past five years in adult cancers.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226838 | PMC |
| http://dx.doi.org/10.3390/cells9040818 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!